EA201792070A1 - Средство для лечения дисфункции лобной доли - Google Patents

Средство для лечения дисфункции лобной доли

Info

Publication number
EA201792070A1
EA201792070A1 EA201792070A EA201792070A EA201792070A1 EA 201792070 A1 EA201792070 A1 EA 201792070A1 EA 201792070 A EA201792070 A EA 201792070A EA 201792070 A EA201792070 A EA 201792070A EA 201792070 A1 EA201792070 A1 EA 201792070A1
Authority
EA
Eurasian Patent Office
Prior art keywords
disease
cognitive impairment
levi
dysfunction
treatment
Prior art date
Application number
EA201792070A
Other languages
English (en)
Other versions
EA032511B1 (ru
Inventor
Такако Хорита
Original Assignee
Киова Хакко Кирин Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Киова Хакко Кирин Ко., Лтд. filed Critical Киова Хакко Кирин Ко., Лтд.
Publication of EA201792070A1 publication Critical patent/EA201792070A1/ru
Publication of EA032511B1 publication Critical patent/EA032511B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Настоящее изобретение предлагает средство для лечения и/или профилактики, например, дисфункции лобной доли (например, когнитивного нарушения (например, когнитивного нарушения в болезни Паркинсона, когнитивного нарушения, вызванного хроническим стрессом, деменции с тельцами Леви, прогрессирующего надъядерного паралича, лобно-височной деменции и т.д.) и т.д.), болезни телец Леви (например, когнитивного нарушения в болезни Паркинсона, болезни диффузных телец Леви, деменции с тельцами Леви, нарушения движений, связанного с болезнью телец Леви, и т.д.) и т.д., которое содержит соединение, представленное формулой (I), или соответствующую фармацевтически приемлемую соль в качестве активного ингредиента.
EA201792070A 2015-03-19 2016-03-18 Средство для лечения дисфункции лобной доли EA032511B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015055532 2015-03-19
PCT/JP2016/059788 WO2016148308A1 (en) 2015-03-19 2016-03-18 Therapeutic agent for frontal lobe dysfunction

Publications (2)

Publication Number Publication Date
EA201792070A1 true EA201792070A1 (ru) 2018-01-31
EA032511B1 EA032511B1 (ru) 2019-06-28

Family

ID=56919157

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201792070A EA032511B1 (ru) 2015-03-19 2016-03-18 Средство для лечения дисфункции лобной доли

Country Status (39)

Country Link
US (2) US20180042910A1 (ru)
EP (1) EP3270923B1 (ru)
JP (1) JP6869893B2 (ru)
KR (1) KR20170129764A (ru)
CN (1) CN107405341A (ru)
AR (1) AR103972A1 (ru)
AU (1) AU2016234211B2 (ru)
BR (1) BR112017018165A2 (ru)
CA (1) CA2978426A1 (ru)
CL (1) CL2017002351A1 (ru)
CO (1) CO2017008814A2 (ru)
CR (1) CR20170405A (ru)
CY (1) CY1124459T1 (ru)
DK (1) DK3270923T3 (ru)
DO (1) DOP2017000206A (ru)
EA (1) EA032511B1 (ru)
EC (1) ECSP17069712A (ru)
ES (1) ES2884846T3 (ru)
GE (1) GEP20197007B (ru)
HK (1) HK1249059A1 (ru)
HR (1) HRP20211340T1 (ru)
HU (1) HUE055387T2 (ru)
IL (1) IL254196A0 (ru)
JO (1) JO3544B1 (ru)
LT (1) LT3270923T (ru)
MX (1) MX2017012020A (ru)
MY (1) MY196076A (ru)
PE (1) PE20171621A1 (ru)
PL (1) PL3270923T3 (ru)
PT (1) PT3270923T (ru)
RS (1) RS62311B1 (ru)
SG (1) SG11201707012YA (ru)
SI (1) SI3270923T1 (ru)
SV (1) SV2017005527A (ru)
TN (1) TN2017000369A1 (ru)
TW (1) TWI723012B (ru)
UA (1) UA123578C2 (ru)
WO (1) WO2016148308A1 (ru)
ZA (1) ZA201706136B (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113016719B (zh) * 2019-12-24 2022-08-02 复旦大学附属华山医院 一种突触核蛋白病理性快动眼睡眠行为障碍模型的制备法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69834500T2 (de) 1997-09-05 2007-05-03 Kyowa Hakko Kogyo Co., Ltd. Xanthinderivative zur behandlung von hirnischämie
EP3002283B1 (en) * 2003-12-26 2017-06-14 Kyowa Hakko Kirin Co., Ltd. Thiazole derivatives
EP2210891A1 (en) * 2009-01-26 2010-07-28 Domain Therapeutics New adenosine receptor ligands and uses thereof
TWI548411B (zh) * 2009-04-28 2016-09-11 Kyowa Hakko Kirin Co Ltd Exercise disorder treatment
UA113383C2 (xx) * 2009-09-02 2017-01-25 Терапевтичний агент для лікування тривожних розладів
UA110097C2 (uk) * 2009-09-02 2015-11-25 Терапевтичний агент для лікування розладів настрою
WO2012060844A1 (en) * 2010-11-05 2012-05-10 Biotie Therapies, Inc A2a antagonists as cognition and motor function enhancers

Also Published As

Publication number Publication date
SG11201707012YA (en) 2017-09-28
AR103972A1 (es) 2017-06-14
JP6869893B2 (ja) 2021-05-12
BR112017018165A2 (pt) 2018-04-10
TWI723012B (zh) 2021-04-01
EP3270923B1 (en) 2021-05-26
CN107405341A (zh) 2017-11-28
US20210393606A1 (en) 2021-12-23
ZA201706136B (en) 2019-01-30
MX2017012020A (es) 2018-01-30
CR20170405A (es) 2018-01-30
JO3544B1 (ar) 2020-07-05
IL254196A0 (en) 2017-10-31
PE20171621A1 (es) 2017-11-02
TW201705957A (zh) 2017-02-16
EP3270923A4 (en) 2018-11-07
AU2016234211B2 (en) 2020-08-27
EA032511B1 (ru) 2019-06-28
DK3270923T3 (da) 2021-08-23
DOP2017000206A (es) 2017-12-31
TN2017000369A1 (en) 2019-01-16
JP2018508540A (ja) 2018-03-29
CY1124459T1 (el) 2022-07-22
LT3270923T (lt) 2021-09-10
SV2017005527A (es) 2017-10-23
CL2017002351A1 (es) 2018-03-16
ECSP17069712A (es) 2018-02-28
CO2017008814A2 (es) 2018-01-16
SI3270923T1 (sl) 2021-10-29
HK1249059A1 (zh) 2018-10-26
US20180042910A1 (en) 2018-02-15
PL3270923T3 (pl) 2021-12-20
ES2884846T3 (es) 2021-12-13
MY196076A (en) 2023-03-13
RS62311B1 (sr) 2021-09-30
PT3270923T (pt) 2021-08-26
CA2978426A1 (en) 2016-09-22
GEP20197007B (en) 2019-07-25
HRP20211340T1 (hr) 2021-11-26
HUE055387T2 (hu) 2021-11-29
WO2016148308A1 (en) 2016-09-22
KR20170129764A (ko) 2017-11-27
AU2016234211A1 (en) 2017-10-12
UA123578C2 (uk) 2021-04-28
EP3270923A1 (en) 2018-01-24

Similar Documents

Publication Publication Date Title
DOP2019000187A (es) Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo
EA201991693A1 (ru) Производное пиридина в качестве ингибитора ask1 и способ его получения и применения
MY194468A (en) Oxy-fluoropiperidine derivatives as kinase inhhiitor
EA201791802A1 (ru) СШИТЫЕ ДИГИДРО-4H-ПИРАЗОЛО[5,1-c][1,4]ОКСАЗИНИЛОВЫЕ СОЕДИНЕНИЯ И АНАЛОГИ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ЦНС
PH12019500196A1 (en) Compounds and compositions and uses thereof
TN2019000175A1 (en) Benzenesulfonamide compounds and their use as therapeutic agents
MX2018013985A (es) Compuestos de bencenosulfonamida y sus usos como agentes terapéuticos.
MY175445A (en) Tri-cycle compound and applications thereof
NZ746906A (en) Oxaborole esters and uses thereof
EA202090414A1 (ru) Соединения и их применение
EA201692300A1 (ru) Производные карбоксамида
PH12016501198A1 (en) Compounds and compositions for the treatment of parasitic diseases
MX2018008307A (es) Derivado de ascoclorina y uso del mismo como activador de proteina cinasa activada por adenosin monofosfato (ampk).
CO2019013254A2 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
PH12021550452A1 (en) Methods of treating mycobacterial infections using tetracycline compounds
PH12017501955A1 (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer`s disease
EA201792070A1 (ru) Средство для лечения дисфункции лобной доли
EA202190316A1 (ru) Конденсированное производное лактама
MD20160040A2 (ru) Пидотимод для использования при лечении заболеваний ассоциированных с воспалением
CL2020000251A1 (es) Derivado de adamantilmetilamina y uso del mismo como producto farmacéutico.
EA201991269A1 (ru) Профилактический агент, агент, подавляющий начало заболевания, или терапевтический агент для прогрессирующих иммунных демиелинизирующих заболеваний
MX2022000356A (es) Compuesto para tratamiento de combinacion.
PH12017500106A1 (en) Prophylactic or therapeutic agent for a posterior ocular disease
EA201792076A1 (ru) Методы и композиции для внутривенного введения фумаратов для лечения неврологических заболеваний

Legal Events

Date Code Title Description
TC4A Change in name of a patent proprietor in a eurasian patent